• In late April 2026, Corcept Therapeutics reported a first-quarter net loss of US$31.76 million versus net income of US$20.55 million a year earlier, while also raising its 2026 revenue guidance to US$950 million–US$1.05 billion on the back of strong prescription trends and the early FDA approval of Lifyorli for platinum-resistant ovarian cancer.
• At the same time, promising long-term survival data from the Phase 2 DAZALS trial in ALS and an advancing cortisol-modulation pipeline highlight how Corcept is attempting to offset Korlym dependence with new endocrinology, oncology and neurology assets despite recent legal and regulatory setbacks.
• We’ll now examine how stronger 2026 revenue guidance, supported by early Lifyorli uptake, may reshape Corcept Therapeutics’ investment narrative.

This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

Corcept Therapeutics Investment Narrative Recap

To own Corcept Therapeutics today, you need to believe its cortisol modulation platform and new approvals can eventually outweigh Korlym’s legal and regulatory overhang. The raised 2026 revenue guidance, helped by early Lifyorli uptake, strengthens the case for near term top line growth, but does not remove the key risk around Korlym patent litigation and regulatory uncertainty for relacorilant, which still sit at the center of the story.

The most relevant update here is Corcept’s higher 2026 revenue outlook of US$950 million to US$1,050 million, tied to strong hypercortisolism prescriptions and Lifyorli’s ahead of schedule approval. This guidance directly connects the current news to the main bullish catalyst: expanding beyond Korlym with oncology and neurology assets, while trying to manage the impact of legal disputes and recent FDA decisions on relacorilant.

Yet investors should also be aware that if generic Korlym competition accelerates sooner than expected, especially if Corcept’s ongoing appeal fails, then...

Corcept Therapeutics' narrative projects $1.4 billion revenue and $493.8 million earnings by 2029. This requires 21.5% yearly revenue growth and about a $395.6 million earnings increase from $98.2 million today.

Uncover how Corcept Therapeutics' forecasts yield a $67.40 fair value, a 29% upside to its current price.

Exploring Other Perspectives

Before this news, the most pessimistic analysts still assumed Corcept could reach about US$1.8 billion in revenue and US$558.7 million in earnings, but they worried that running many late stage programs at once might push costs ahead of sales growth, so it is worth asking whether the latest guidance and pipeline updates narrow that gap in expectations or make their caution look more reasonable.

Explore 8 other fair value estimates on Corcept Therapeutics - why the stock might be worth over 6x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Corcept Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Corcept Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Corcept Therapeutics' overall financial health at a glance.

Interested In Other Possibilities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.